Latest Drug design Stories
New report monitors emerging drug delivery technologies at 62 younger, emerging companies PLUS it's not too late to register for the Structure-Based Drug Design conference FARMINGTON, Conn., June 5, 2013 /PRNewswire-iReach/ -- From Global Information and MCD Group, a new report "Early Stage Drug Delivery Technologies" profiles 62 start-ups and small companies that have interest in forming new partnerships or receiving funding to enable further development and eventual...
-This is the first study that studies and quantifies 1,600 known adverse effects of drugs currently on the market. -The scientists Miquel Duran and Patrick Aloy provide a description of the molecular processes responsible for more than 1,000 secondary effects. -This knowledge, which is available to the scientific community, may be of great use to minimize and predict adverse effects during drug design. Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory...
SAN DIEGO, March 7, 2013 /PRNewswire/ -- Receptos, a biopharmaceutical company focused on developing therapeutic candidates directed to G-protein-coupled receptor (GPCR) targets, announced today that it has successfully determined a novel protein crystal structure of an undisclosed proprietary GPCR drug discovery target for Ono Pharmaceuticals. In December 2011, Ono entered into a technology collaboration to access Receptos' proprietary GPCR structure determination technology...
WELWYN GARDEN CITY, England and BOSTON, September 10, 2012 /PRNewswire/ -- Update on novel structures and product pipeline to be presented at Biochemical Society and Royal Society of Chemistry meetings Heptares Therapeutics today announces that it has used its StaR(R) technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR). Chief Scientific Officer, Fiona Marshall and Chief Executive...
Watch the Video: MU Research Team Creates Potent Cancer Drug Lee Rannals for redOrbit.com - Your Universe Online Medicinal chemists have rolled up their sleeves and created a new cancer drug that is 10 times as potent as current drugs. The team set out to take an existing drug being developed to fight certain cancers, added special structures to it, and created an even more powerful weapon to combat the deadly affliction. "Over the past decade, we have seen an increasing interest...
SAN DIEGO, July 13, 2012 /PRNewswire/ -- Receptos Inc. announced today the co-publication, in conjunction with the Stevens Lab at The Scripps Research Institute®, of key results relating to its expertise in the determination of high resolution G-protein coupled receptor (GPCR) crystal structures to enable rational drug discovery and design, including for allosteric modulators of GPCR receptors. The article, published in today's issue of Science and titled "Structural Basis for...
Connie K. Ho for redOrbit.com – Your Universe Online Alcohol and drugs are just a few of the things that can possibly be found at play in a nightclub. Scientists from the University of Copenhagen (UC) recently studied the effects of a particular drug called Fantasy. With their studies, the UC researchers revealed that they were able to gain a better understanding of the biological makeup of gamma-hydroxbutryic acid (GHB,) a transmitter substance found in the brain. GHB is related to...
Scientists at the University of Copenhagen have previously documented that substances from the South African plant species Crinum and Cyrtanthus – akin to snowdrops and daffodils – have an effect on the mechanisms in the brain that are involved in depression. This research has now yielded further results, since a team based at the Faculty of Health and Medical Sciences has recently shown how several South African flowers contain plant compounds whose characteristics enable them to...
BRUSSELS, June 20, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced the release of Accelrys Discovery Studio(®) 3.5 modeling and simulation software during the company's European Science Symposium in Brussels. The latest release extends Discovery Studio's portfolio of small-molecule ligand design and market-leading biological simulation tools, including a new, validated ligand-profiling...
A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects. Rather than seeking to find magic bullets — chemicals that specifically attack one gene or protein involved in one particular part of a disease process — the new approach looks to find “magic shotguns” by...
